DRL gears up for biosimilar push, consumer health growth post record FY25
Dr Reddy’s stock rose 5.5% in six sessions post-Q4 results, outperforming the BSE Healthcare index. Strong revenue growth, biosimilar launches, and semaglutide portfolio support long-term prospects despite Revlimid taper and reduced target prices by (...)
Site référencé: The Economic Times
The Economic Times
Mind Over Money : Shaji Varghese on discipline, purpose, and wellness : 5 lessons from 3 dozen marathons
18/05/2025
Breakout Stocks : How to trade Mazagon Dock, Bharat Dynamics & Bharat Electronics that hit fresh 52-week high ?
18/05/2025
Trump shrugs off Netanyahu on gulf tour
18/05/2025
3 mutual fund NFOs will open for subscription this week
18/05/2025
Sectoral and thematic mutual funds took lead last week
18/05/2025
FIIs pump Rs 23,778 cr into Indian stocks in May. Is more buying seen ahead ?
17/05/2025
